๐ Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected. ยฉ 2013, Mary Ann Liebert, Inc.
keywords
๐ spike protein (353)
๐ significantly higher (104)
๐ neutralizing antibodies (122)
๐ infectious disease (312)
๐ virus replication (219)
๐ respiratory syndrome (2004)
๐ acute respiratory (1734)
author
๐ค Li, Jie
๐ค Ulitzky, Laura
๐ค Silberstein, Erica
๐ค Taylor, Deborah R.
๐ค Viscidi, Raphael
year
โฐ 2013
journal
๐ Viral Immunology
issn
๐ 08828245 15578976
volume
26
number
2
page
126-132
citedbycount
12
download
๐ [BibTeX]